Merck's shot, called Capvaxive, specifically protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease that can spread to other parts of the body and lead to ...

(Bloomberg) -- Merck & Co. won US approval for a pneumococcal vaccine that threatens to unseat one of Pfizer Inc.’s biggest franchises. Called Capvaxive, Merck’s vaccine is approved to prevent ...

Merck’s new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair, have the potential to generate significant revenues for Merck over the long ...

With Capvaxive, MSD (known as Merck & Co in the US and Canada) is aiming to carve out a niche in the over-50s, positioning it as the go-to vaccine used to prevent invasive pneumococcal disease ...

Following FDA approval, CAPVAXIVE was unanimously recommended by the CDC’s Advisory Committee on Immunization Practices for pneumococcal vaccination for certain adults. In addition, Merck ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults ...

Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults, ...